Ibrutinib for Patients with Relapsed/Refractory CLL and Association of Complex Karyotype with Outcomes


Ibrutinib for Patients with Relapsed/Refractory CLL and Association of Complex Karyotype with Outcomes
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jonathan W Friedberg, MD, MMSc (1/8/15)
O’Brien S et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: Results from the phase II RESONATE-17 trial. Proc ASH 2014;Abstract 327.

Thompson PA et al. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens. Proc ASH 2014;Abstract 22.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.